Evidence map›Paper›PMID 42601521›Full record

Observational studyClinical rheumatology2026

Comparative effectiveness and predictors of SRI-4 and LLDAS attainment in active systemic lupus erythematosus: a real-world study of telitacicept versus belimumab.

Xinyi Shen, Qingyi Chen, Lei Wang, Tingting Wu, Jian Wu, Erye Zhou, Tian Ren, Jing Cao, Yufeng Yin, Tao Cheng and 1 more

Abstract readObservational StudyComparative Study
PubMed Publisher
In one paragraph

Observational study in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xinyi ShenDepartment of Rheumatology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, China.
Qingyi ChenDepartment of Rheumatology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, China.
Lei WangDepartment of Rheumatology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, China.
Tingting WuDepartment of Rheumatology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, China.
Jian WuDepartment of Rheumatology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, China.
Erye ZhouDepartment of Rheumatology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, China.
Tian RenDepartment of Rheumatology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, China.
Jing CaoDepartment of Rheumatology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, China.
Yufeng YinDepartment of Rheumatology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, China. yinyufeng@126.com.
Tao ChengDepartment of Rheumatology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, China. chengtao0526@126.com.
Mingjun WangDepartment of Rheumatology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, China. 81489895@qq.com.ORCID http://orcid.org/0009-0003-8595-3782

Funding

Gusu Health Talent Research Project GSWS2023040Medical Innovation Application of Suzhou Science and Technology Bureau SKY2023161ScientificResearch Project of Soochow University P112202223
6 · The paper itself

Abstract

objectiveTo compare the attainment of Systemic Lupus Erythematosus Responder Index 4 (SRI-4) and lupus low disease activity state (LLDAS) between telitacicept and belimumab in patients with active systemic lupus erythematosus (SLE), and to identify baseline clinical predictors of treatment response.

methodsThis retrospective observational cohort study was conducted at a single center in China between 2020 and 2024. A total of 115 patients with active SLE received either telitacicept (n = 60, 80 mg or 160 mg weekly) or belimumab (n = 55, 10 mg/kg every 4 weeks) alongside standard therapy. The primary outcome was the SRI-4 response rate at week 24. Baseline predictors were identified using LASSO and multivariable Cox proportional hazards models.

resultsTelitacicept demonstrated a significantly higher early SRI-4 response at week 4 (16.7% [10/60] vs. 3.6% [2/55]; OR 5.30, 95% CI 1.11-25.39, P = 0.037). At week 24, the SRI-4 response was 56.7% (34/60) for telitacicept compared to 40.0% (22/55) for belimumab (OR 1.96, 95% CI 0.93-4.12, P = 0.075). Univariate Cox analysis indicated a superior cumulative SRI-4 incidence for telitacicept (HR 3.03, 95% CI 1.30-7.08, P = 0.011). Multivariable analysis confirmed baseline SLEDAI-2 K (HR 1.29, 95% CI 1.17-1.42, P = 0.001) and serum albumin levels (HR 1.16, 95% CI 1.08-1.24, P = 0.001) as independent predictors of SRI-4 achievement. The incidence of total adverse events was comparable between the telitacicept and belimumab groups (38.3% [23/60] vs. 34.6% [19/55], P = 0.675).

conclusionsIn clinical practice, telitacicept is associated with earlier SRI-4 attainment compared to belimumab in patients with active SLE. Baseline disease activity scores and serum albumin levels are key prognostic markers for achieving therapeutic response. Key Points • Telitacicept is associated with a significantly more rapid attainment of the SRI-4 response compared to belimumab in patients with active systemic lupus erythematosus in a real-world setting. • Baseline SLEDAI-2 K scores and serum albumin levels are identified as independent predictors for achieving early therapeutic responses. • The two BAFF/APRIL inhibitors exhibit distinct hematological impacts: telitacicept significantly improves hemoglobin levels, while belimumab is more effective at increasing platelet counts. • A higher dose of telitacicept (160 mg) may facilitate superior long-term attainment of the lupus low disease activity state (LLDAS) compared to the standard dose.

Indexed as

Antibodies, Monoclonal, HumanizedImmunosuppressive AgentsLupus Erythematosus, SystemicAdultChinaFemaleHumansMaleMiddle AgedRecombinant Fusion ProteinsRetrospective StudiesSeverity of Illness IndexTreatment OutcomeAntibodies, Monoclonal, HumanizedbelimumabImmunosuppressive AgentsRecombinant Fusion ProteinstelitaciceptBelimumabLupus low disease activity statePredictorSystemic lupus erythematosusTelitacicept

Identifiers

PMID42601521

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.